Related Experiment Videos
Dopa-responsive dystonia -- the story so far
1Department of Neurology, Philipps-University, Marburg, Germany. Bandmann@mailer.uni-marburg.de
Neuropediatrics
|April 4, 2002
Summary
Dopa-responsive dystonia (DRD) is a treatable genetic disorder causing early-onset walking difficulties and parkinsonian symptoms. It results from reduced dopamine due to tetrahydrobiopterin (BH4) deficiency caused by GTP cyclohydrolase I gene mutations.
Area of Science:
- Neurogenetics
- Biochemistry
- Pediatric Neurology
Background:
- Dopa-responsive dystonia (DRD) presents with early-onset dystonia and parkinsonian features.
- Biochemical hallmarks include low homovanillic acid, neopterin, and tetrahydrobiopterin (BH4) in cerebrospinal fluid.
- DRD is primarily caused by mutations in the GTP cyclohydrolase I gene, affecting BH4 synthesis.
Purpose of the Study:
- To summarize current knowledge on Dopa-responsive dystonia (DRD).
- To highlight recent genetic advances and phenotypic variability.
- To emphasize clinical aspects, including diagnostic challenges and atypical presentations.
Main Methods:
- Literature review of Dopa-responsive dystonia (DRD).
- Analysis of genetic mutations and their impact on BH4 synthesis.
- Clinical case review focusing on diagnostic criteria and presentation.
Main Results:
- Mutations in GTP cyclohydrolase I gene lead to BH4 deficiency, impairing dopamine synthesis.
- Reduced BH4 impacts tyrosine hydroxylase activity, causing a dopamine-deficit syndrome.
- Other implicated genes include TH and parkin; phenotypes can be diverse, including infantile and early childhood presentations.
Conclusions:
- DRD is a treatable condition crucial to recognize.
- Understanding the genetic basis and expanding phenotype aids diagnosis.
- Early identification and management are vital for patients with DRD.